{"gao_id": "GAO-22-105042", "published": "2021-11-19T12:00:00Z", "released": "2021-11-19T07:00:00Z", "summary": "Antibiotic- and antifungal-resistant infections pose a serious public health issue. Yet there may not be a sufficient number of drugs in development to meet this threat. The Food and Drug Administration can use its \"limited population pathway process\" to approve antibacterial and antifungal drugs for rare, serious or life-threatening infections. It doesn't change FDA's approval process, but does offer tools to help FDA accept greater...", "title": "Drug Development: Pathway for Approving Antibacterial and Antifungal Drugs for Patients with Limited Treatment Options is Infrequently Used", "topics": ["Clinical trials", "Drug approvals", "Drug safety", "Tuberculosis", "New drugs", "Health Care", "Antimicrobial resistance", "Health care", "Health care standards", "Drugs", "Patient care"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-22-105042", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-22-105042-highlights.pdf"}, {"title": "Full Report (24 pages)", "url": "https://www.gao.gov/assets/gao-22-105042.pdf"}, {"title": "Accessible PDF (26 pages)", "url": "https://www.gao.gov/assets/720/717655.pdf"}]}